| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MIR17HG | Enterovirus 71 (GDFS-3 strain of EV 71) | 10^2 TCID50/mL ;
24 hr |
RD Human embryonal rhabdomyosarcoma cells | RNA-Seq | 2.997594 | Upregulation | p < 0.05 | GeneSpring GX v12.0 software package (Agilent Technologies) | Not provided | 2013 | 23220233 |
| MIR17HG | Enterovirus 71 (GDFS-3 strain of EV 71) | 10^2 TCID50/mL ;
24 hr |
RD Human embryonal rhabdomyosarcoma cells | RNA-Seq | 2.5827105 | Upregulation | p < 0.05 | GeneSpring GX v12.0 software package (Agilent Technologies) | Not provided | 2013 | 23220233 |
| MIR17HG | Coxsackie virus B3 (CG strain of CVB3) | MOI = 0.5 ;
23 hr |
HeLa Human papillomavirus-related endocervical adenocarcinoma cells | Microarray | 2.3589103 | Upregulation | 0.000141 | GeneSpring GX v11.5.1 software package (Agilent Technologies) | student's t test | 2019 | 31388922 |
| MIR17HG | Coxsackie virus B3 (CG strain of CVB3) | MOI = 0.5 ;
23 hr |
HeLa Human papillomavirus-related endocervical adenocarcinoma cells | Microarray | 2.4094963 | Upregulation | 0.000141 | GeneSpring GX v11.5.1 software package (Agilent Technologies) | student's t test | 2019 | 31388922 |
| MIR17HG | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells | RNA-Seq | 1.584667323 | Upregulation | 0.00693376 | student's t test | 2020 | 32416070 | |
| MIR17HG | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 2.027806511 | Upregulation | 0.026181121 | student's t test | 2020 | 32416070 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose